ometendoОжирение и метаболизмObesity and metabolism2071-87132306-5524Endocrinology Research Centre10.14341/2071-8713-4907ometendo-4907Research ArticleСтатьиArticlesЭффективное лечение ожирения путем влияния на снижение потребления пищи и повышение расхода энергииEffektivnoe lechenie ozhireniya putem vliyaniya na snizhenie potrebleniya pishchi i povyshenie raskhoda energiiMkrtumyanA M-PodachinaS V-20071503200741№1 (2007)1518Copyright © Mkrtumyan A.M., Podachina S.V., 20072007Mkrtumyan A.M., Podachina S.V.Mkrtumyan A.M., Podachina S.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.omet-endojournals.ru/jour/article/view/4907ReferencesAronne L.J., Segal R.K. Adiposity and fat distribution outcome measures: assessment and clinical implications. Obes Res. 2002; 10(1): 14S-21S.Aronne L.J., Segal R.K. Adiposity and fat distribution outcome measures: assessment and clinical implications. Obes Res. 2002; 10(1): 14S-21S.Barbato J.E., Zuckerbraun B.S., Overhaus M., et al. Nitric oxide modulates vascular inflammation and intimal hyperplasia in insulin resistance and metabolic syndrome. Am J Physiol Heart Circ Physiol. 2005; 289:H228-H236.Barbato J.E., Zuckerbraun B.S., Overhaus M., et al. Nitric oxide modulates vascular inflammation and intimal hyperplasia in insulin resistance and metabolic syndrome. Am J Physiol Heart Circ Physiol. 2005; 289:H228-H236.Caballero A.E. Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. Obesity Research. 2003; 11:1278-89.Caballero A.E. Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. Obesity Research. 2003; 11:1278-89.Couillard C., Bergeron N., Prud'homme D., et al. Postprandial triglyceride response in visceral obesity in men. Diabetes. 1998; 47: 953-960.Couillard C., Bergeron N., Prud'homme D., et al. Postprandial triglyceride response in visceral obesity in men. Diabetes. 1998; 47: 953-960.Kahn B.B., Flier J.S. Obesity and insulin resistance. J Clin Invest. 2000; 106:473-81.Kahn B.B., Flier J.S. Obesity and insulin resistance. J Clin Invest. 2000; 106:473-81.Miller J., Rosenbloom A., Silverstein J. Childhood obesity. J Clin Endocrinol Metabol. 2004; 89-9:4211-18.Miller J., Rosenbloom A., Silverstein J. Childhood obesity. J Clin Endocrinol Metabol. 2004; 89-9:4211-18.Nagi D.K., Yudkin J.S. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects.Nagi D.K., Yudkin J.S. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects.A study of two ethnic groups. Diabetes Care. 1993; 16 (4): 621-629.A study of two ethnic groups. Diabetes Care. 1993; 16 (4): 621-629.Ожирение / под ред. И.И. Дедова, Г.А. Мельниченко. М.: Медицинское информационное агентство, 2004.Ожирение / под ред. И.И. Дедова, Г.А. Мельниченко. М.: Медицинское информационное агентство, 2004.Bray G.A., Greenway F.L. Current and potential drugs for treatment of obesity. Endocr Rev 1999; 20:805-75.Bray G.A., Greenway F.L. Current and potential drugs for treatment of obesity. Endocr Rev 1999; 20:805-75.Fisher B.L., Schauer P. Medical and surgical options in the treatment of severe obesity. Am. J. Surg. 2002; 184: 9-16.Fisher B.L., Schauer P. Medical and surgical options in the treatment of severe obesity. Am. J. Surg. 2002; 184: 9-16.Poston W.S.C., Foreyt J.P. Sibutramin and the management of obesity. Expert. Opin. Pharmacoter. 2004; 5: 633-642.Poston W.S.C., Foreyt J.P. Sibutramin and the management of obesity. Expert. Opin. Pharmacoter. 2004; 5: 633-642.Sjostrom L., Rissanen A., Andersen T., et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998; 352:167-72.Sjostrom L., Rissanen A., Andersen T., et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998; 352:167-72.Julia A Ello-Martin et al. Am J Clin Nutr 2005; 82(suppl): 236S-41S.Julia A Ello-Martin et al. Am J Clin Nutr 2005; 82(suppl): 236S-41S.Van Gaal et al. Endocrinologia Metabolismo & Nutrio. Sep 2006; 15(5):270. Abst. CO 30.Van Gaal et al. Endocrinologia Metabolismo & Nutrio. Sep 2006; 15(5):270. Abst. CO 30.
The authors declare that there are no conflicts of interest present.